These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 35510314

  • 1. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
    Lelegren MJ, Son SY, Han JK, Lam KK.
    Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, Qiu H, Huang X, Yang Q.
    Int Arch Allergy Immunol; 2022 Jun; 183(3):279-288. PubMed ID: 34607329
    [Abstract] [Full Text] [Related]

  • 5. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A, Soler ZM, Smith TL, Mace JC, Schlosser RJ.
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biologics in Chronic Rhinosinusitis: Current and Emerging.
    Boyd JT, Khanwalkar AR.
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):657-671. PubMed ID: 39389716
    [Abstract] [Full Text] [Related]

  • 8. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
    Hardison SA, Senior BA.
    J Otolaryngol Head Neck Surg; 2023 Sep 28; 52(1):64. PubMed ID: 37759322
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
    De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA.
    Am J Rhinol Allergy; 2022 Nov 28; 36(6):788-795. PubMed ID: 35837739
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review.
    Kim C, Han J, Wu T, Bachert C, Fokkens W, Hellings P, Hopkins C, Lee S, Mullol J, Lee JT.
    Otolaryngol Head Neck Surg; 2021 Jan 28; 164(1):57-66. PubMed ID: 32746710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C.
    J Allergy Clin Immunol; 2020 Sep 28; 146(3):595-605. PubMed ID: 32524991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.